In this video, Lachelle Weeks, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the current approach to surveillance and intervention in individuals with clonal hematopoiesis of indeterminate potential (CHIP) or clonal cytopenia of undetermined significance (CCUS), emphasizing that widespread screening for these precursor conditions in the adult population is not recommended due to a lack of approved therapeutic interventions. Dr Weeks suggests that patients with known CHIP or CCUS should discuss their individual risk with a provider, develop a personalized surveillance strategy, and consider clinical trial enrolment if eligible. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
